chr11-108321385-T-G
Variant summary
Our verdict is Likely benign. Variant got -1 ACMG points: 0P and 1B. BP6
The NM_000051.4(ATM):āc.6537T>Gā(p.Ile2179Met) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0000341 in 1,614,080 control chromosomes in the GnomAD database, with no homozygous occurrence. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars).
Frequency
Consequence
NM_000051.4 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Likely_benign. Variant got -1 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
ATM | NM_000051.4 | c.6537T>G | p.Ile2179Met | missense_variant | Exon 45 of 63 | ENST00000675843.1 | NP_000042.3 |
Ensembl
Frequencies
GnomAD3 genomes AF: 0.000197 AC: 30AN: 152208Hom.: 0 Cov.: 32
GnomAD3 exomes AF: 0.0000398 AC: 10AN: 251448Hom.: 0 AF XY: 0.0000221 AC XY: 3AN XY: 135888
GnomAD4 exome AF: 0.0000171 AC: 25AN: 1461872Hom.: 0 Cov.: 31 AF XY: 0.0000165 AC XY: 12AN XY: 727240
GnomAD4 genome AF: 0.000197 AC: 30AN: 152208Hom.: 0 Cov.: 32 AF XY: 0.000202 AC XY: 15AN XY: 74368
ClinVar
Submissions by phenotype
not provided Uncertain:4
In silico analysis indicates that this missense variant does not alter protein structure/function; Reported in a breast/prostate cancer case-control study, with no significant difference in frequency between cases and controls (PMID: 23555315); Observed in individuals with a personal and/or family history of breast cancer, as well as an individual with pheochromocytoma/paraganglioma (PMID: 25186627, 31206626, 35264596, 35980532, 36568162, 37529773); This variant is associated with the following publications: (PMID: 28093192, 25186627, 32832836, 31206626, 35264596, 35980532, 37529773, 36568162, 39324485, 23532176, 23555315) -
- -
- -
Available data are insufficient to determine the clinical significance of the variant at this time. The frequency of this variant in the general population is higher than would generally be expected for pathogenic variants in this gene (http://gnomad.broadinstitute.org). Computational tools disagree on the variant's effect on normal protein function. -
Ataxia-telangiectasia syndrome Uncertain:3
- -
- -
This sequence change replaces isoleucine, which is neutral and non-polar, with methionine, which is neutral and non-polar, at codon 2179 of the ATM protein (p.Ile2179Met). This variant is present in population databases (rs146243469, gnomAD 0.05%). This missense change has been observed in individual(s) with breast cancer (PMID: 25186627, 35264596). ClinVar contains an entry for this variant (Variation ID: 186221). Invitae Evidence Modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) indicates that this missense variant is not expected to disrupt ATM protein function with a negative predictive value of 95%. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. -
Hereditary cancer-predisposing syndrome Uncertain:3
- -
The p.I2179M variant (also known as c.6537T>G), located in coding exon 44 of the ATM gene, results from a T to G substitution at nucleotide position 6537. The isoleucine at codon 2179 is replaced by methionine, an amino acid with highly similar properties. This variant has been reported in multiple individuals with features consistent with ATM-related cancer predisposition (Tung N et al. Cancer, 2015 Jan;121:25-33; Pereira JZ et al. Mol Biol Rep, 2022 Oct;49:9509-9520; Guindalini RSC et al. Sci Rep, 2022 Mar;12:4190; van der Merwe NC et al. Front Oncol, 2022 Dec;12:938561). This amino acid position is well conserved in available vertebrate species. In addition, the in silico prediction for this alteration is inconclusive. Based on the available evidence, the clinical significance of this variant remains unclear. -
This missense variant replaces isoleucine with methionine at codon 2179 of the ATM protein. Computational prediction suggests that this variant may not impact protein structure and function. To our knowledge, functional studies have not been reported for this variant. This variant has not been reported in individuals affected with ATM-related disorders in the literature. This variant has been identified in 15/282848 chromosomes in the general population by the Genome Aggregation Database (gnomAD). The available evidence is insufficient to determine the role of this variant in disease conclusively. Therefore, this variant is classified as a Variant of Uncertain Significance. -
Familial cancer of breast Uncertain:1Benign:1
This variant is considered likely benign. This variant is strongly associated with less severe personal and family histories of cancer, typical for individuals without pathogenic variants in this gene [PMID: 25085752]. -
- -
not specified Uncertain:1
Variant summary: ATM c.6537T>G (p.Ile2179Met) results in a conservative amino acid change located in the FAT domain (IPR003151) of the encoded protein sequence. Three of five in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 0.0002 in 150980 control chromosomes, predominantly at a frequency of 0.00068 within the African or African-American subpopulation in the gnomAD database (v3.1 genomes dataset). This frequency is somewhat lower than the estimated maximum expected for a pathogenic variant in ATM causing Breast Cancer (0.001), allowing no conclusion about variant significance. However, the variant was also reported in the FLOSSIES database in 7/2559 African American women (i.e. with an allele frequency of 0.001367), who were older than age 70 years who have never had cancer, suggesting that the variant is likely benign. c.6537T>G has been reported in the literature, predominately as a VUS in settings of multigene panel testing, in individuals affected with Breast Cancer or other tumor phenotype(s), who are primarily of Hispanic- or African ancestry, without strong evidence for causality (e.g. Haiman_2013, Tung_2014, Weitzel_2019, Pereira_2022, van der Merwe_2022, Guindalini_2022, Lima_2023). These reports do not provide unequivocal conclusions about association of the variant with Breast Cancer. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. The following publications have been ascertained in the context of this evaluation (PMID: 35264596, 23555315, 35980532, 25186627, 31206626, 36568162, 37529773). ClinVar contains an entry for this variant (Variation ID: 186221). Based on the evidence outlined above, the variant was classified as VUS-possibly benign. -
Ataxia-telangiectasia syndrome;C0346153:Familial cancer of breast Uncertain:1
- -
ATM-related disorder Uncertain:1
The ATM c.6537T>G variant is predicted to result in the amino acid substitution p.Ile2179Met. This variant has been reported in an individual with breast cancer (Tung et al. 2015. PubMed ID: 25186627) and an individual with leiomyosarcoma (Lee et al. 2017. PubMed ID: 28093192). It was reported in a GWAS study of breast and prostate cancer risk in a multiethnic population (Haiman et al. 2013. PubMed ID: 23555315, Table S6.2). This variant is reported in 0.056% of alleles in individuals of African descent in gnomAD and is interpreted as uncertain significance by the vast majority of laboratories in ClinVar (https://www.ncbi.nlm.nih.gov/clinvar/variation/186221/). At this time, the clinical significance of this variant is uncertain due to the absence of conclusive functional and genetic evidence. -
Hereditary breast ovarian cancer syndrome Uncertain:1
- -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at